Guangdong Association of Clinical Trials
Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
- Conditions
- Interventions
- First Posted Date
- 2024-11-29
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 342
- Registration Number
- NCT06709274
- Locations
- 🇨🇳
Dongguan People's Hospital, Dongguan, Guangdong, China
🇨🇳The First People's Hospital of Foshan, Foshan, Guangdong, China
🇨🇳Guangdong Provincial People's Hostpital, Guangzhou, Guangdong, China
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 50
- Registration Number
- NCT06282874
- Locations
- 🇨🇳
Guangdong Provincial Perople's Hospital, Guangzhou, Other (Non U.s.), China
Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 126
- Registration Number
- NCT06092086
- Locations
- 🇨🇳
Guangdong Provincial Perople's Hospital, Guangzhou, Guangdong, China
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 36
- Registration Number
- NCT05957510
- Locations
- 🇨🇳
Guangdong Provincial Perople's Hospital, Guangzhou, Guangdong, China
Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 180
- Registration Number
- NCT05536505
- Locations
- 🇨🇳
Chongqing University Three Gorges Hospital, Chongqing, China
🇨🇳The First People's Hospital of Foshan, Foshan, China
🇨🇳Beijing Friendship Hospital, Capital Medical University, Beijing, China
Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD
- Conditions
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 180
- Registration Number
- NCT05457049
- Locations
- 🇨🇳
Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China
Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC
- Conditions
- Interventions
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 44
- Registration Number
- NCT05163249
- Locations
- 🇨🇳
Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China
Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 90
- Registration Number
- NCT04988607
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model.
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 192
- Registration Number
- NCT04841811
- Locations
- 🇨🇳
Guangdong Lung cancer institute, Guangzhou, Guangdong, China
Efficacy and Safety of Camrelizumab in Real-World Prospective Study
- Conditions
- First Posted Date
- 2021-03-11
- Last Posted Date
- 2021-03-11
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 1000
- Registration Number
- NCT04793139